Zacks Investment Research
16 Nov 2026, 23:46 UTC · 1h ago
Aytu BioPharma, Inc. (AYTU) Reports Q1 Loss, Beats Revenue Estimates
Impact · against what's priced in
Aytu BioPharma's Q1 results are mixed, with a revenue beat offset by a significant earnings miss. The widening loss per share to $0.20, double the expected $0.10, outweighs the marginal 2.36% revenue surprise.
- AYTU−0.30
No priced-in read yet
- In context
The company reported a quarterly loss of $0.2 per share, which is double the $0.1 consensus estimate and a significant increase from the $0.08 loss a year ago, offsetting a slight revenue beat of $14.84 million.
Read from the article alone

Search tags




